Agouron Pharmaceuticals, Inc.

Effector Therapeutics, Inc.

Siegfried Heinz Reich

John Howard Tatlock

Vincent J Kalish

Michael J Rodriguez

Justin T Ernst

Paul A Sprengeler

Stephen Evan Webber

Michael Brennan Wallace

Stephen W Kaldor

Alan X Xiang

Bruce Anthony Dressman

Timothy Alan Shepherd

James E Fritz

John E Munroe

William Joseph Hornback

Theodore Otto Johnson, Jr

Ted Michael Bleckman

Michael D Varney

Marlys Hammond

Susan Elizabeth Kephart

Hiep The Luu

Ye Hua

Chinh Viet Tran

Samuel Sperry

Min Teng

Peter Scott Dragovich

Robert Steven Kania

Cynthia Louise Palmer

Steven Lee Bender

Michael Raymond Collins

Garrick Kenneth Packard

Allen Borchardt

Thomas Jay Prins

William Henry Romines, Iii

Stephan James Cripps

Michael David Johnson

Donald James Skalitzky

Christine Thomas

Christian Nilewski

Theo Michels

Thomas L Little, Jr

Joseph Timothy Marakovits

Robert E Babine

Michael J Melnick

Yi Yang

Shao Song Chu

Ethel S Littlefield

Brian Walter Eastman

Gary Louis Bolton

David J Kucera

Bennett C Borer

Maria Angelica Linton

Mark Robert Barvian

Frederick Earl Boyer

Anna Maria Tempczyk-Russell

Tanya Michelle Jewell

Benjamin Joseph Burke

Lennert J Mitchell, Jr

Thomas Francis Hendrickson

Jo Ann Z Wilson

Anna Marie Tempczyk-Russell

Stacie S Canan Koch

Therese N Alexander

Scott C Virgil

Stephen T Worland

Jeffrey J Machak

Tod Holler

Sean T Murphy

Vara Prasad Josyula

Mike Shaghafi

Fora P Chan

Louis Nickolaus Jungheim

Ru Zhou

Indrawan James McAlpine

Wesley Kwan Mung Chong

Rohit Kumar Duvadie

Lin Li

Kaveri Urkalan

Larry Andrew Alegria

Yuanjin Rui

Michael J Rodriquez

Anthony J Trippe

Dzuy T Nguyen

Mark J Pino

Mary Ann Fuhry

Alan Grubbs

Kathleen Lewis

Takasuke Mukaiyama

Douglas Murphy

Alan Xin Xiang

Theodore Michels

The present invention provides crystalline solids of 6′-((6-aminopyrimidin-4-yl)amino)-8′-methyl-2′H-spiro[cyclohexane-1,3′-imidazo[1,5-a]pyridine]-1′,5′-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

Crystalline forms of Mnk inhibitors

The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof wherein X, X, R, R, Rand n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula (I) compounds as well as methods for utilizing the compounds of Formula (I) and the pharmaceutically acceptable compositions of Formula (I) compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.

Piperidine-substituted Mnk inhibitors and methods related thereto

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.  For Formula I compounds X, Y, R, R, R, R, R, Rand Rare as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

EIF4A-inhibiting compounds and methods related thereto

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.  For Formula I compounds X, X, X, X, X, X, Q, L, L, Y, R, R, R, R, R, R, R, Rand rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

EIF4E-inhibiting compounds and methods

The present invention provides crystalline solids of 6'-((6-aminopyrimidin-4-yl)amino)-8&#x2032;-methyl-2&#x2032;H-spiro[cyclohexane-1,3&#x2032;-imidazo[1,5-a]pyridine]-1&#x2032;,5&#x2032;-dione: The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

Crystalline forms of MNK inhibitors

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I. or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A, A. A, A, A, A, A, W, R, R, R, R, R, R, R, R, R, R, R, R, R, R, R, Rand Rand subscripts 'm' and 'n' are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit MNK1 and MNK2

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I or Formula II, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, X, X, X, X, Y, Y, R, R, R, R, R, R, R, R, R, R, R, Rand Rare as defined in the specification. The inventive Formula I and Formula II compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

Benzimidazole-indole inhibitors of Mnk1 and Mnk2

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R, R, R, R, R, Rand Rare as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds A, A, A, A, A, W, Y, R, R, R, R, R, R, R, R, R, R, R, R, R, R, and Rand subscript 'n' are as defined in the specification. The inventive Formula I compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2

eIF4A-inhibiting compounds and methods related thereto

The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, R, R, R, W, W, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.

MNK inhibitors and methods related thereto

Mnk inhibitors and methods related thereto

Indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating, e.g., kinases-dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation

Growing community of inventors

Solana Beach, CA, United States of America

Siegfried Heinz Reich